The Longest Shortest Time | 13 March 2019 | 0h 40m | Listen Later | iTunes
Interview with Dani Shapiro about her book Inheritance: A Memoir of Genealogy, Paternity, and Love. A moving account of uncovering her father’s identity after surprising results from a consumer DNA test.
Science Vs | 12 April 2019 | 0h 38m | Listen Later | iTunes
Millions of people send off their DNA to companies like Ancestry.com and 23andme to find out where they come from, and what diseases they might get. Explores how much you can trust these DNA kits with anthropologist Jonathan Marks and geneticist Adam Rutherford.
The One You Feed | 20 June 2018 | 0h 42m | Listen Later | iTunes
Interview with Andrew Solomon about his books Far From the Tree: Parents, Children, and the Search for Identity and The Noonday Demon: An Atlas of Depression. Particularly insightful on the challenges and joys of parenting disabled children; celebrating our difficulties and differences; and approaches to treating depression.
Startup Podcast | 25 March 2019 | 0h 46m | Listen Later | iTunes
Enthralling story of Paul Holes working for decades on the Golden State Killer case.
The Guardian’s Audio Long Reads | 25 March 2019 | 0h 28m | Listen Later | iTunes
Primatologist Frans de Waal on why animal politics are not so different from our own. Stresses that even in the wild, leadership is about much more than being a bully.
Masters in Business | 28 March 2019 | 1h 24m | Listen Later | iTunes
Deliciously wonky interview with Joshua Miller about the ideas in his paper Surprised By the Hot Hand Fallacy? A Truth in the Law of Small Numbers, which he co-authored with Adam Sanjurjo. Discusses in an accessible way the statistical concepts behind proving that hot hands do exist, thus confirming our intuition and disproving one of the famous examples of behavioural economics.
EconTalk | 1 April 2019 | 1h 18m | Listen Later | iTunes
Interview with Jacob Stegenga about his book Medical Nihilism. Stegenga argues that many medical treatments either fail to achieve their intended goals or achieve those goals with many negative side effects. Stegenga argues that the approval process for pharmaceuticals, for example, exaggerates benefits and underestimates costs. He criticizes the FDA approval process for approving too many drugs that are not sufficiently helpful relative to their side effects. Stegenga argues for a more realistic understanding of what medical practice can and cannot achieve.